Sweden: Martin-Löf to leave CFO role at Oncopeptides

Anders Martin-Löf, CFO Oncopeptides

Oncopeptides, a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases, has announced that CFO Anders Martin-Löf will leave the company for personal reasons. Martin-Löf, who was appointed CFO in 2018 will continue in his current role until a new temporary or permanent CFO takes office. He has a six-month…

You must be a HMI Subscriber to view this content.

Subscribe Now »

Advertisement